𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular magnetic resonance imaging with targeted contrast agents

✍ Scribed by Dmitri Artemov


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
104 KB
Volume
90
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Magnetic resonance imaging (MRI) produces high‐resolution three‐dimensional maps delineating morphological features of the specimen. Differential contrast in soft tissues depends on endogenous differences in water content, relaxation times, and/or diffusion characteristics of the tissue of interest. The specificity of MRI can be further increased by exogenous contrast agents (CA) such as gadolinium chelates, which have been successfully used for imaging of hemodynamic parameters including blood perfusion and vascular permeability. Development of targeted MR CA directed to specific molecular entities could dramatically expand the range of MR applications by combining the noninvasiveness and high spatial resolution of MRI with specific localization of molecular targets. However, due to the intrinsically low sensitivity of MRI (in comparison with nuclear imaging), high local concentrations of the CA at the target site are required to generate detectable MR contrast. To meet these requirements, the MR targeted CA should recognize targeted cells with high affinity and specificity. They should also be characterized by high relaxivity, which for a wide variety of CA depends on the number of contrast‐generating groups per single molecule of the agent. We will review different designs and applications of targeted MR CA and will discuss feasibility of these approaches for in vivo MRI. © 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Magnetic resonance imaging of inflammati
✍ Sébastien Boutry; Carmen Burtea; Sophie Laurent; Gérard Toubeau; Luce Vander Els 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 457 KB

## Abstract E‐selectin‐targeted contrast enhancement of blood vessels in inflamed tissues was investigated with a new contrast agent, Gd‐DTPA‐B(sLe^x^)A, which was recently obtained by grafting a synthetic mimetic of sialyl‐Lewis^x^, an E‐selectin ligand, onto Gd‐DTPA. The pharmacokinetics, biodist